We have also investigated combinations of pretreatment B2M and HLA levels relative to tumor PD-L1 expression and CD8+ tumor infiltration, which are known biomarkers for response to checkpoint inhibitor therapy (37, 38, 43). The gene discussed is B2M; the disease is neoplasm.